Explore our materials

Filters

Results (14539)

Viral Hepatitis and Liver Disease

Symposium on Key Issues in Liver Transplantation for NASH 2016

Optimizing Immunosuppression | Mohammed Siddiqui

Viral Hepatitis and Liver Disease

Symposium on Key Issues in Liver Transplantation for NASH 2016

Panel Discussion

Viral Hepatitis and Liver Disease

Symposium on Key Issues in Liver Transplantation for NASH 2016

How should we optimize immunosuppression? - Kittie Wynne, MD, PhD

Viral Hepatitis and Liver Disease

Symposium on Key Issues in Liver Transplantation for NASH 2016

What is an acceptable BMI - Lee Kaplan, MD, PhD

Viral Hepatitis and Liver Disease

Symposium on Key Issues in Liver Transplantation for NASH 2016

Can Bariatric surgery convert a non-candidate to a candidate? - Julie Heimbachx, MD

Dmitry Manuilov

MD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

Update on the Efficacy and Safety of Bulevirtide for Treatment of Chronic HDV - D. Manuilov, MD

Douglas Mayers

MD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

Active Site Polymerase Inhibitor Nucleotides (APSINs) - D. Mayers, MD

Matthew McClure

MD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

STOPS Agents - M. McClure, MD

Leigh Felton

BSc, PhD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

Antisense Oligos - L. Felton, Bsc, PhD

Luisa Stamm

MD, PhD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

Core Inhibitors (Capsid Assembly Modulators) - Luisa Stamm, MD, PhD

Stephan Urban

PhD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

Biological Insights Taught by Clinical Responses to Novel Hbv-Hdv Drugs - S. Urban, PhD

Poonam Mishra

MD, MPH, FAASLD

Viral Hepatitis and Liver Disease

International Workshop on HBV Cure 2021

Safety Monitoring during HBV Clinical Trials and after Antiviral Discontinuation - P. Mishra, MD, MPH, FAASLD